Current Edition

Bevacizumab leads clinical trial activity for monoclonal antibodies, says GlobalData

When tracking clinical trial activity across the world, GlobalData, a leading data and analytics company, identified 5,273 industry monoclonal antibodies (mAb) clinical trials with a start date between January 1, 2007, and December 31, 2016.

GlobalData analysed the dataset to identify the top drugs investigated in industry-sponsored clinical trials in mAbs. The top three drugs were bevacizumab, adalimumab, and tocilizumab. Making up the top ten were rituximab, nivolumab, pembrolizumab, ranibizumab, secukinumab, trastuzumab, and ipilimumab.
Marco Borria, Healthcare Analyst at GlobalData, commented: “All the top ten drugs are marketed and the majority of the trials initiated for these drugs were Phase III trials, closely followed by Phase IV and Phase II. However, the largest share of bevacizumab trials were in Phase II, with 35% of trials occurring in indications for which the drug has not yet been approved.”